Nantbio, Inc.

Nant Holdingsip, LLC

Nantomics, LLC

Nantbioscience, Inc.

Paul Weingarten

Chunlin Tao

Shahrooz Rabizadeh

Qinwei Wang

Patrick Soon-Shiong

Kayvan R Niazi

Stephen Charles Benz

Oleksandr V Buzko

Heather McFarlane

Forrest Arp

David G Ho

Laxman Nallan

Sherry Ci

Chengzhi Yu

Connie Tsai

Anna B Juncker-Jensen

Sharif Asad

Justin Golovato

Christopher W Szeto

David T Ho

Tulay Polat

Heather Mcfarlane

David Ho

Niazi Kayvan

Anna Juncker-Jensen

The present inventive subject matter provides apparatus, systems, and methods in which a diagnostic test is identified, where the diagnostic test is for determining whether a particular treatment is effective for a particular patient based on one or more characteristics of a patient's cells. When a treatment is developed with the potential to treat one or more diseases, the drug can have different effects on different cell lines related to the diseases. A machine learning system is programmed to infer a measurable cell characteristic, out of many different measurable cell characteristics, that has a desirable correlation with the sensitivity data of different cell lines to a treatment. The machine learning system is programmed to then determine, based on the correlation, a threshold level of the cell characteristic the patient should exhibit in order to recommend administering the treatment.

Pathway analysis for identification of diagnostic tests

The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Trk inhibition

The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.

Pyrimidine derivatives as kinase inhibitors and their therapeutical applications

Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.

Compositions and methods of Rit1 inhibition

The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.

Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

Compositions and methods of targeting mutant K-RAS

Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

Compositions and methods of targeting mutant K-ras

The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.

Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway

Growing community of inventors

Anaheim, CA, United States of America

Paul Weingarten